Pelvital, a women’s health MedTech company on a mission to transform the standard of care for urinary incontinence, has announced the publication of a landmark review paper “Transvaginal mechanotherapy for stress urinary incontinence: Principles, cellular and neuromuscular mechanisms of action, and comparison to current gold standard treatments” in the peer-reviewed journal Continence Reports.
The article underscores the significant benefits and efficacy of transvaginal mechanotherapy, which promotes muscular, cellular, and neuromuscular rehabilitation, as a first-line, non-invasive, and accessible treatment for stress urinary incontinence (SUI).
This review article found that women who used transvaginal mechanotherapy experienced significant improvements in both pad weight reduction and quality of life. Additionally, outcomes were superior to pelvic floor muscle training and comparable to surgical interventions, offering a highly effective, non-invasive alternative.
Unlike traditional options including invasive procedures, pelvic floor therapy, or pads, transvaginal mechanotherapy is an at-home treatment that can be easily incorporated into a woman’s daily routine, reducing barriers to care, and avoiding the risks associated with more intrusive options.
“I am proud to be a part of this crucial article that highlights the evidence behind transvaginal mechanotherapy as a groundbreaking advancement for the millions of women struggling with stress urinary incontinence,” says Leah Fulker, DPT and Pelvital Patient Support Manager
“There is a significant gap in care for women with urinary incontinence, leaving many without access to effective treatment options. By prescribing this first-line conservative treatment that is used in the home, Family Medicine and OB/Gyn physicians can bridge this gap, providing women with a safe, effective, and accessible solution that delivers lasting results and significantly improves quality of life.”
Transvaginal mechanotherapy superimposed on pelvic floor muscle training increases the efficacy of an already widely accepted conservative gold standard SUI treatment, allowing patients to achieve both their short and long-term continence goals with greater efficacy and a shorter treatment time.
“Pelvital is committed to advancing the science of women’s health and expanding access to effective, evidence-based treatments,” says Lydia Zeller, CEO of Pelvital. “This paper validates the effectiveness of transvaginal mechanotherapy as a first-line treatment and reinforces our mission to provide clinicians and women with a proven, accessible, non-invasive solution.”
